QQ客服 官方微博 反馈留言

	Exposure-Response-based Product-Profile-driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
	Rui Zhu; Bill Poland; Russ Wada; Qi Liu; Luna Musib; Daniel Maslyar; Eunpi Cho; Wei Yu; Han Ma; Jin Yan Jin
刊名	CPT: pharmacometrics & systems pharmacology
	2019
关键词	Benefit-risk assessment clinical utility index dose selection exposure-response ipatasertib
ISSN号	2163-8306
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4737773
专题	湖南大学
作者单位	Genentech, Inc, South San Francisco, CA, USA. Certara, CA, USA.
推荐引用方式 GB/T 7714	Rui Zhu,Bill Poland,Russ Wada,et al. Exposure-Response-based Product-Profile-driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.[J]. CPT: pharmacometrics & systems pharmacology,2019.
APA	Rui Zhu.,Bill Poland.,Russ Wada.,Qi Liu.,Luna Musib.,...&Nageshwar Budha.(2019).Exposure-Response-based Product-Profile-driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer..CPT: pharmacometrics & systems pharmacology.
MLA	Rui Zhu,et al."Exposure-Response-based Product-Profile-driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.".CPT: pharmacometrics & systems pharmacology (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。